Abstracts from ASH 2019

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma 

Robert J Lin, et al.

Older patients should not be excluded from CAR T based on chronologic age alone; these results highlight potential benefits of CAR T in selected older patients even with functional limitation, multi-morbidity, and significant tumor burden; and the lack of excessive CRS, NT, and other high-grade toxicities.

Abstract n. 1603

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, et al.

Efficacy outcomes in the commercial setting appear similar to responses seen in the pivotal clinical trials. Though different toxicity grading scales were employed, tisa-cel appears to be associated with less CRS and NEs.

Abstract n. 1599

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Marjorie E Zettler, et al.

This large-scale post-marketing report of CAR T-cell therapy associated AEs provides real-world evidence for use of CAR T-cell therapy in patients ≥65 and reports patterns of AEs observed based on age.

Abstract n. 1951

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

Jérôme Paillassa, et al.

Intensity of bridging therapies (BT) was heterogeneous and closely related to tumor burden at enrollment. High intensity BT (HI chemotherapy+/-immunotherapy) and low intensity BT (LI, including monoclonal antibodies rituximab, brentuximab, dexamethasone, lenalidomide) showed no significant difference in efficacy, but a higher frequency of CRES was observed in the HI group.

Abstract n. 2886

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Stephan Grupp, et al.

In the real-world, tisa-cel has similar efficacy and improved safety in pediatric ALL patients. OOS product (viability 60-80%) does not impact efficacy

Abstract n. 2619